- Home
- XNCR vs BAK Comparison
XNCR vs BAK Comparison
Compare XNCR & BAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XNCR
- BAK
- Stock Information
- Founded
- XNCR 1997
- BAK 1972
- Country
- XNCR United States
- BAK Brazil
- Employees
- XNCR N/A
- BAK N/A
- Industry
- XNCR Biotechnology: Pharmaceutical Preparations
- BAK Major Chemicals
- Sector
- XNCR Health Care
- BAK Industrials
- Exchange
- XNCR Nasdaq
- BAK Nasdaq
- Market Cap
- XNCR 1.7B
- BAK 1.7B
- IPO Year
- XNCR 2013
- BAK N/A
- Fundamental
- Price
- XNCR $20.45
- BAK $4.82
- Analyst Decision
- XNCR Strong Buy
- BAK Strong Buy
- Analyst Count
- XNCR 9
- BAK 3
- Target Price
- XNCR $36.33
- BAK $9.75
- AVG Volume (30 Days)
- XNCR 766.2K
- BAK 945.2K
- Earning Date
- XNCR 02-25-2025
- BAK 11-06-2024
- Dividend Yield
- XNCR N/A
- BAK N/A
- EPS Growth
- XNCR N/A
- BAK N/A
- EPS
- XNCR N/A
- BAK N/A
- Revenue
- XNCR $85,164,000.00
- BAK $13,764,416,401.00
- Revenue This Year
- XNCR N/A
- BAK $14.98
- Revenue Next Year
- XNCR $80.86
- BAK $8.32
- P/E Ratio
- XNCR N/A
- BAK N/A
- Revenue Growth
- XNCR N/A
- BAK 2.86
- 52 Week Low
- XNCR $15.31
- BAK $3.69
- 52 Week High
- XNCR $27.24
- BAK $10.98
- Technical
- Relative Strength Index (RSI)
- XNCR 38.80
- BAK 65.56
- Support Level
- XNCR $19.15
- BAK $3.69
- Resistance Level
- XNCR $24.66
- BAK $4.03
- Average True Range (ATR)
- XNCR 1.14
- BAK 0.16
- MACD
- XNCR -0.37
- BAK 0.14
- Stochastic Oscillator
- XNCR 24.96
- BAK 97.40
About XNCR Xencor Inc.
Xencor Inc is a clinical-stage biopharmaceutical company based in the United States. It focuses on discovering and developing engineered monoclonal antibody and other protein therapeutics to treat severe and life-threatening diseases such with unmet medical needs. The company uses its XmAb technology platform to create antibody product candidates such as XmAb5871 and XmAb7195. It also has a few pre-clinical stage candidates in its portfolio such as XmAb14045, XmAb662 among others. It earns its revenue from research and development collaborations and licenses of its internally developed drug candidates.
About BAK Braskem SA ADR
Braskem SA manufactures and sells chemicals, petrochemicals, fuels, and utilities. The company's geographical segments include Brazil; the United States and Europe and Mexico. It derives a majority of its revenue from Brazil. It produces olefins, such as ethylene, polymer and chemical-grade propylene, butadiene, and butene-1; fuels, such as automotive gasoline, liquefied petroleum gas, or LPG, ethyl tertiary-butyl ether, or ETBE, and methyl tertiary-butyl ether, or MTBE; intermediates, such as cumene and others.